Vanguard Capital Management
TARS icon

Vanguard Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Vanguard Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113M Buy
1,793,064
+32,523
+2% +$2.08M ﹤0.01% 1502
2026
Q1 		$124M Buy
+1,760,541
New +$123M ﹤0.01% 1358

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management's TARS Position: Q2 2026 in Review

Vanguard Capital Management increased its Tarsus Pharmaceuticals (TARS) stake by 1.8% in Q2 2026, buying an estimated $2.08M and bringing the position to 1,793,064 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Vanguard Capital Management first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. The position peaked at $124M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Vanguard Capital Management held 1,793,064 shares of Tarsus Pharmaceuticals worth $113M as of Q2 2026.
  • Vanguard Capital Management bought 32,523 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.08M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1502 holding.
  • Vanguard Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Tarsus Pharmaceuticals position peaked at $124M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.